Flex Pharma’s Proprietary ElectroNanoSpray™ Platform Enables Second FDA-Approved 505(b)(2) Oncology Product
The approval of CAVHANZA™ follows PHYRAGO®, demonstrating a repeatable path from proprietary particle engineering to differentiated, FDA-approved medicines NEW BRIGHTON,…